Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.

Frontiers in endocrinology - 1 Jan 2020

Tong Anli, Li Ming, Cui Yunying, Ma Xiaosen, Wang Huiping, Li Yuxiu

Abstract excerpt

Context: Metastatic pheochromocytoma/paraganglioma (MPP) therapy mainly involves radionuclide therapy, chemotherapy, and targeted therapy. In recent years, temozolomide (TMZ) showed great promise in some MMP patients, especially those with SDHB germline mutation. We reported a patient with MPP who did not have any known germline genetic change and responded remarkably well to TMZ monotherapy. Case presentation:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Paraganglioma

Share to Pheochromocytoma

Share to Succinate Dehydrogenase

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 32132978
DOI: 10.3389/fendo.2020.00061
PMCID: PMC7040234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.PMID 32132978Read ↗

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.Semantic proximity Read ↗

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitorsSemantic proximity Read ↗

Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.Semantic proximity Read ↗

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB TumorsSemantic proximity Read ↗

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.Semantic proximity Read ↗

Paraganglioma Presenting Atypical Initial Symptoms: a Case ReportSemantic proximity Read ↗

Metastatic paraganglioma.Semantic proximity Read ↗

Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.Semantic proximity Read ↗

Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroupsSemantic proximity Read ↗

Role of [68Ga]DOTANOC PET/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study.Semantic proximity Read ↗

Malignant pheochromocytoma.Semantic proximity Read ↗

Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.